APO Research
Talk to an analyst

APO RESEARCH · REPORT

Kidney Cancer or Renal Cancer

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Kidney Cancer or Renal Cancer Market Analysis and Forecast 2026-2032

29 December 2025190 pages

Choose your research edition.

Industry ResearchKidney Cancer or Renal Cancer Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Kidney Cancer or Renal Cancer Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Kidney Cancer or Renal Cancer Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Kidney Cancer or Renal Cancer Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Kidney Cancer or Renal Cancer Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Kidney Cancer or Renal Cancer market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Kidney Cancer or Renal Cancer is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Kidney Cancer or Renal Cancer is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Kidney Cancer or Renal Cancer is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Kidney Cancer or Renal Cancer is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Kidney Cancer or Renal Cancer include Takeda, Novartis, Merck & Co, Roche, Pfizer, Seagen, Merck KGaA, GSK and Gilead Sciences, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Kidney Cancer or Renal Cancer, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Kidney Cancer or Renal Cancer, also provides the revenue of main regions and countries. Of the upcoming market potential for Kidney Cancer or Renal Cancer, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Kidney Cancer or Renal Cancer revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Kidney Cancer or Renal Cancer market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Kidney Cancer or Renal Cancer revenue, projected growth trends, production technology, application and end-user industry.

Kidney Cancer or Renal Cancer Segment by Company

Takeda

Novartis

Merck & Co

Roche

Pfizer

Seagen

Merck KGaA

GSK

Gilead Sciences

Eli Lilly

Bristol-Myers Squibb

AstraZeneca

Amgen

Kidney Cancer or Renal Cancer Segment by Type

Targeted Therapy

Chemotherapy

Immunotherapy

Kidney Cancer or Renal Cancer Segment by Application

Hospital

Pharmacy

Other

Kidney Cancer or Renal Cancer Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Kidney Cancer or Renal Cancer market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Kidney Cancer or Renal Cancer and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Kidney Cancer or Renal Cancer.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Kidney Cancer or Renal Cancer in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Kidney Cancer or Renal Cancer company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Kidney Cancer or Renal Cancer revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Kidney Cancer or Renal Cancer Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Targeted Therapy Major Player Table 3. Chemotherapy Major Player Table 4. Immunotherapy Major Player Table 5. Global Kidney Cancer or Renal Cancer Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Hospital Major Player Table 7. Pharmacy Major Player Table 8. Other Major Player Table 9. Kidney Cancer or Renal Cancer Industry Trends Table 10. Kidney Cancer or Renal Cancer Industry Drivers Table 11. Kidney Cancer or Renal Cancer Industry Opportunities and Challenges Table 12. Kidney Cancer or Renal Cancer Industry Restraints Table 13. Global Kidney Cancer or Renal Cancer Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global Kidney Cancer or Renal Cancer Market Size by Region (2021-2026) & (US$ Million) Table 15. Global Kidney Cancer or Renal Cancer Market Share by Region (2021-2026) Table 16. Global Kidney Cancer or Renal Cancer Market Size by Region (2027-2032) & (US$ Million) Table 17. Global Kidney Cancer or Renal Cancer Market Share by Region (2027-2032) Table 18. Global Kidney Cancer or Renal Cancer Revenue by Players (US$ Million) & (2021-2026) Table 19. Global Kidney Cancer or Renal Cancer Revenue Market Share by Players (2021-2026) Table 20. Global Kidney Cancer or Renal Cancer Key Players Ranking, 2024 VS 2025 VS 2026 Table 21. Global Kidney Cancer or Renal Cancer Key Players Headquarters & Area Served Table 22. Global Kidney Cancer or Renal Cancer Players, Product Type & Application Table 23. Global Kidney Cancer or Renal Cancer Players Establishment Date Table 24. Global Players Market Concentration Ratio (CR5 and HHI) Table 25. Global Kidney Cancer or Renal Cancer by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 26. Global Kidney Cancer or Renal Cancer Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Kidney Cancer or Renal Cancer Revenue by Type (2021-2026) & (US$ Million) Table 28. Global Kidney Cancer or Renal Cancer Revenue by Type (2027-2032) & (US$ Million) Table 29. Global Kidney Cancer or Renal Cancer Revenue Market Share by Type (2021-2026) Table 30. Global Kidney Cancer or Renal Cancer Revenue Market Share by Type (2027-2032) Table 31. Global Kidney Cancer or Renal Cancer Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Kidney Cancer or Renal Cancer Revenue by Application (2021-2026) & (US$ Million) Table 33. Global Kidney Cancer or Renal Cancer Revenue by Application (2027-2032) & (US$ Million) Table 34. Global Kidney Cancer or Renal Cancer Revenue Market Share by Application (2021-2026) Table 35. Global Kidney Cancer or Renal Cancer Revenue Market Share by Application (2027-2032) Table 36. Takeda Company Information Table 37. Takeda Business Overview Table 38. Takeda Kidney Cancer or Renal Cancer Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. Takeda Kidney Cancer or Renal Cancer Product Portfolio Table 40. Takeda Recent Development Table 41. Novartis Company Information Table 42. Novartis Business Overview Table 43. Novartis Kidney Cancer or Renal Cancer Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. Novartis Kidney Cancer or Renal Cancer Product Portfolio Table 45. Novartis Recent Development Table 46. Merck & Co Company Information Table 47. Merck & Co Business Overview Table 48. Merck & Co Kidney Cancer or Renal Cancer Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. Merck & Co Kidney Cancer or Renal Cancer Product Portfolio Table 50. Merck & Co Recent Development Table 51. Roche Company Information Table 52. Roche Business Overview Table 53. Roche Kidney Cancer or Renal Cancer Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. Roche Kidney Cancer or Renal Cancer Product Portfolio Table 55. Roche Recent Development Table 56. Pfizer Company Information Table 57. Pfizer Business Overview Table 58. Pfizer Kidney Cancer or Renal Cancer Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. Pfizer Kidney Cancer or Renal Cancer Product Portfolio Table 60. Pfizer Recent Development Table 61. Seagen Company Information Table 62. Seagen Business Overview Table 63. Seagen Kidney Cancer or Renal Cancer Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. Seagen Kidney Cancer or Renal Cancer Product Portfolio Table 65. Seagen Recent Development Table 66. Merck KGaA Company Information Table 67. Merck KGaA Business Overview Table 68. Merck KGaA Kidney Cancer or Renal Cancer Revenue and Gross Margin (US$ Million) & (2021-2026) Table 69. Merck KGaA Kidney Cancer or Renal Cancer Product Portfolio Table 70. Merck KGaA Recent Development Table 71. GSK Company Information Table 72. GSK Business Overview Table 73. GSK Kidney Cancer or Renal Cancer Revenue and Gross Margin (US$ Million) & (2021-2026) Table 74. GSK Kidney Cancer or Renal Cancer Product Portfolio Table 75. GSK Recent Development Table 76. Gilead Sciences Company Information Table 77. Gilead Sciences Business Overview Table 78. Gilead Sciences Kidney Cancer or Renal Cancer Revenue and Gross Margin (US$ Million) & (2021-2026) Table 79. Gilead Sciences Kidney Cancer or Renal Cancer Product Portfolio Table 80. Gilead Sciences Recent Development Table 81. Eli Lilly Company Information Table 82. Eli Lilly Business Overview Table 83. Eli Lilly Kidney Cancer or Renal Cancer Revenue and Gross Margin (US$ Million) & (2021-2026) Table 84. Eli Lilly Kidney Cancer or Renal Cancer Product Portfolio Table 85. Eli Lilly Recent Development Table 86. Bristol-Myers Squibb Company Information Table 87. Bristol-Myers Squibb Business Overview Table 88. Bristol-Myers Squibb Kidney Cancer or Renal Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Bristol-Myers Squibb Kidney Cancer or Renal Cancer Product Portfolio Table 90. Bristol-Myers Squibb Recent Development Table 91. AstraZeneca Company Information Table 92. AstraZeneca Business Overview Table 93. AstraZeneca Kidney Cancer or Renal Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. AstraZeneca Kidney Cancer or Renal Cancer Product Portfolio Table 95. AstraZeneca Recent Development Table 96. Amgen Company Information Table 97. Amgen Business Overview Table 98. Amgen Kidney Cancer or Renal Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Amgen Kidney Cancer or Renal Cancer Product Portfolio Table 100. Amgen Recent Development Table 101. North America Kidney Cancer or Renal Cancer Revenue by Type (2021-2026) & (US$ Million) Table 102. North America Kidney Cancer or Renal Cancer Revenue by Type (2027-2032) & (US$ Million) Table 103. North America Kidney Cancer or Renal Cancer Revenue by Application (2021-2026) & (US$ Million) Table 104. North America Kidney Cancer or Renal Cancer Revenue by Application (2027-2032) & (US$ Million) Table 105. North America Kidney Cancer or Renal Cancer Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 106. North America Kidney Cancer or Renal Cancer Revenue by Country (2021-2026) & (US$ Million) Table 107. North America Kidney Cancer or Renal Cancer Revenue by Country (US$ Million) & (2027-2032) Table 108. Europe Kidney Cancer or Renal Cancer Revenue by Type (2021-2026) & (US$ Million) Table 109. Europe Kidney Cancer or Renal Cancer Revenue by Type (2027-2032) & (US$ Million) Table 110. Europe Kidney Cancer or Renal Cancer Revenue by Application (2021-2026) & (US$ Million) Table 111. Europe Kidney Cancer or Renal Cancer Revenue by Application (2027-2032) & (US$ Million) Table 112. Europe Kidney Cancer or Renal Cancer Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 113. Europe Kidney Cancer or Renal Cancer Revenue by Country (2021-2026) & (US$ Million) Table 114. Europe Kidney Cancer or Renal Cancer Revenue by Country (US$ Million) & (2027-2032) Table 115. China Kidney Cancer or Renal Cancer Revenue by Type (2021-2026) & (US$ Million) Table 116. China Kidney Cancer or Renal Cancer Revenue by Type (2027-2032) & (US$ Million) Table 117. China Kidney Cancer or Renal Cancer Revenue by Application (2021-2026) & (US$ Million) Table 118. China Kidney Cancer or Renal Cancer Revenue by Application (2027-2032) & (US$ Million) Table 119. Asia Kidney Cancer or Renal Cancer Revenue by Type (2021-2026) & (US$ Million) Table 120. Asia Kidney Cancer or Renal Cancer Revenue by Type (2027-2032) & (US$ Million) Table 121. Asia Kidney Cancer or Renal Cancer Revenue by Application (2021-2026) & (US$ Million) Table 122. Asia Kidney Cancer or Renal Cancer Revenue by Application (2027-2032) & (US$ Million) Table 123. Asia Kidney Cancer or Renal Cancer Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 124. Asia Kidney Cancer or Renal Cancer Revenue by Region (US$ Million) & (2021-2026) Table 125. Asia Kidney Cancer or Renal Cancer Revenue by Region (US$ Million) & (2027-2032) Table 126. SAMEA Kidney Cancer or Renal Cancer Revenue by Type (2021-2026) & (US$ Million) Table 127. SAMEA Kidney Cancer or Renal Cancer Revenue by Type (2027-2032) & (US$ Million) Table 128. SAMEA Kidney Cancer or Renal Cancer Revenue by Application (2021-2026) & (US$ Million) Table 129. SAMEA Kidney Cancer or Renal Cancer Revenue by Application (2027-2032) & (US$ Million) Table 130. SAMEA Kidney Cancer or Renal Cancer Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 131. SAMEA Kidney Cancer or Renal Cancer Revenue by Country (2021-2026) & (US$ Million) Table 132. SAMEA Kidney Cancer or Renal Cancer Revenue by Country (US$ Million) & (2027-2032) Table 133. Research Programs/Design for This Report Table 134. Authors List of This Report Table 135. Secondary Sources Table 136. Primary Sources List of Figures Figure 1. Kidney Cancer or Renal Cancer Image Figure 2. Global Kidney Cancer or Renal Cancer Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Kidney Cancer or Renal Cancer Market Size Share 2021 VS 2025 VS 2032 Figure 4. Targeted Therapy Image Figure 5. Chemotherapy Image Figure 6. Immunotherapy Image Figure 7. Global Kidney Cancer or Renal Cancer Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Kidney Cancer or Renal Cancer Market Size Share 2021 VS 2025 VS 2032 Figure 9. Hospital Image Figure 10. Pharmacy Image Figure 11. Other Image Figure 12. Global Kidney Cancer or Renal Cancer Market Size (US$ Million) & (2021-2032) Figure 13. Global Kidney Cancer or Renal Cancer Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Kidney Cancer or Renal Cancer Market Share by Region: 2021 VS 2025 VS 2032 Figure 15. Global Kidney Cancer or Renal Cancer Players Revenue Share Top 10 and Top 5 in 2025 Figure 16. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 17. Global Kidney Cancer or Renal Cancer Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Kidney Cancer or Renal Cancer Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Kidney Cancer or Renal Cancer Revenue Market Share by Type (2021-2032) Figure 20. Global Kidney Cancer or Renal Cancer Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Kidney Cancer or Renal Cancer Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 22. Global Kidney Cancer or Renal Cancer Revenue Market Share by Application (2021-2032) Figure 23. North America Kidney Cancer or Renal Cancer Revenue YoY Growth (2021-2032) & (US$ Million) Figure 24. North America Kidney Cancer or Renal Cancer Revenue Share by Type (2021-2032) Figure 25. North America Kidney Cancer or Renal Cancer Revenue Share by Application (2021-2032) Figure 26. North America Kidney Cancer or Renal Cancer Revenue Share by Country (2021-2032) Figure 27. United States Kidney Cancer or Renal Cancer Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Canada Kidney Cancer or Renal Cancer Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Mexico Kidney Cancer or Renal Cancer Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Europe Kidney Cancer or Renal Cancer Revenue YoY Growth (2021-2032) & (US$ Million) Figure 31. Europe Kidney Cancer or Renal Cancer Revenue Share by Type (2021-2032) Figure 32. Europe Kidney Cancer or Renal Cancer Revenue Share by Application (2021-2032) Figure 33. Europe Kidney Cancer or Renal Cancer Revenue Share by Country (2021-2032) Figure 34. Germany Kidney Cancer or Renal Cancer Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. France Kidney Cancer or Renal Cancer Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. U.K. Kidney Cancer or Renal Cancer Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Italy Kidney Cancer or Renal Cancer Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Spain Kidney Cancer or Renal Cancer Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Russia Kidney Cancer or Renal Cancer Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Netherlands Kidney Cancer or Renal Cancer Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Nordic Countries Kidney Cancer or Renal Cancer Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. China Kidney Cancer or Renal Cancer Revenue YoY Growth (2021-2032) & (US$ Million) Figure 43. China Kidney Cancer or Renal Cancer Revenue Share by Type (2021-2032) Figure 44. China Kidney Cancer or Renal Cancer Revenue Share by Application (2021-2032) Figure 45. Asia Kidney Cancer or Renal Cancer Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. Asia Kidney Cancer or Renal Cancer Revenue Share by Type (2021-2032) Figure 47. Asia Kidney Cancer or Renal Cancer Revenue Share by Application (2021-2032) Figure 48. Asia Kidney Cancer or Renal Cancer Revenue Share by Region (2021-2032) Figure 49. Japan Kidney Cancer or Renal Cancer Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. South Korea Kidney Cancer or Renal Cancer Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. India Kidney Cancer or Renal Cancer Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Australia Kidney Cancer or Renal Cancer Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Taiwan Kidney Cancer or Renal Cancer Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Southeast Asia Kidney Cancer or Renal Cancer Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. SAMEA Kidney Cancer or Renal Cancer Revenue YoY Growth (2021-2032) & (US$ Million) Figure 56. SAMEA Kidney Cancer or Renal Cancer Revenue Share by Type (2021-2032) Figure 57. SAMEA Kidney Cancer or Renal Cancer Revenue Share by Application (2021-2032) Figure 58. SAMEA Kidney Cancer or Renal Cancer Revenue Share by Country (2021-2032) Figure 59. Brazil Kidney Cancer or Renal Cancer Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Argentina Kidney Cancer or Renal Cancer Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Chile Kidney Cancer or Renal Cancer Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Colombia Kidney Cancer or Renal Cancer Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Peru Kidney Cancer or Renal Cancer Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Saudi Arabia Kidney Cancer or Renal Cancer Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Israel Kidney Cancer or Renal Cancer Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. UAE Kidney Cancer or Renal Cancer Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Turkey Kidney Cancer or Renal Cancer Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Iran Kidney Cancer or Renal Cancer Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Egypt Kidney Cancer or Renal Cancer Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Targeted Therapy
  • Chemotherapy
  • Immunotherapy
Applications
  • Hospital
  • Pharmacy
  • Other
Companies covered
  • Takeda
  • Novartis
  • Merck & Co
  • Roche
  • Pfizer
  • Seagen
  • Merck KGaA
  • GSK
  • Gilead Sciences
  • Eli Lilly
  • Bristol-Myers Squibb
  • AstraZeneca
  • Amgen

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Kidney Cancer or Renal Cancer Market by Type
  3. 1.2.1 Global Kidney Cancer or Renal Cancer Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Targeted Therapy
  5. 1.2.3 Chemotherapy
  6. 1.2.4 Immunotherapy
  7. 1.3 Kidney Cancer or Renal Cancer Market by Application
  8. 1.3.1 Global Kidney Cancer or Renal Cancer Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Hospital
  10. 1.3.3 Pharmacy
  11. 1.3.4 Other
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 Kidney Cancer or Renal Cancer Market Dynamics
  1. 2.1 Kidney Cancer or Renal Cancer Industry Trends
  2. 2.2 Kidney Cancer or Renal Cancer Industry Drivers
  3. 2.3 Kidney Cancer or Renal Cancer Industry Opportunities and Challenges
  4. 2.4 Kidney Cancer or Renal Cancer Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Kidney Cancer or Renal Cancer Market Perspective (2021-2032)
  2. 3.2 Global Kidney Cancer or Renal Cancer Growth Trends by Region
  3. 3.2.1 Global Kidney Cancer or Renal Cancer Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Kidney Cancer or Renal Cancer Market Size by Region (2021-2026)
  5. 3.2.3 Global Kidney Cancer or Renal Cancer Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Kidney Cancer or Renal Cancer Revenue by Players
  2. 4.1.1 Global Kidney Cancer or Renal Cancer Revenue by Players (2021-2026)
  3. 4.1.2 Global Kidney Cancer or Renal Cancer Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Kidney Cancer or Renal Cancer Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Kidney Cancer or Renal Cancer Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Kidney Cancer or Renal Cancer Key Players Headquarters & Area Served
  7. 4.4 Global Kidney Cancer or Renal Cancer Players, Product Type & Application
  8. 4.5 Global Kidney Cancer or Renal Cancer Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Kidney Cancer or Renal Cancer Market CR5 and HHI
  11. 4.6.3 2025 Kidney Cancer or Renal Cancer Tier 1, Tier 2, and Tier 3
5 Kidney Cancer or Renal Cancer Market Size by Type
  1. 5.1 Global Kidney Cancer or Renal Cancer Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Kidney Cancer or Renal Cancer Revenue by Type (2021-2032)
  3. 5.3 Global Kidney Cancer or Renal Cancer Revenue Market Share by Type (2021-2032)
6 Kidney Cancer or Renal Cancer Market Size by Application
  1. 6.1 Global Kidney Cancer or Renal Cancer Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Kidney Cancer or Renal Cancer Revenue by Application (2021-2032)
  3. 6.3 Global Kidney Cancer or Renal Cancer Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Takeda
  2. 7.1.1 Takeda Company Information
  3. 7.1.2 Takeda Business Overview
  4. 7.1.3 Takeda Kidney Cancer or Renal Cancer Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Takeda Kidney Cancer or Renal Cancer Product Portfolio
  6. 7.1.5 Takeda Recent Developments
  7. 7.2 Novartis
  8. 7.2.1 Novartis Company Information
  9. 7.2.2 Novartis Business Overview
  10. 7.2.3 Novartis Kidney Cancer or Renal Cancer Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Novartis Kidney Cancer or Renal Cancer Product Portfolio
  12. 7.2.5 Novartis Recent Developments
  13. 7.3 Merck & Co
  14. 7.3.1 Merck & Co Company Information
  15. 7.3.2 Merck & Co Business Overview
  16. 7.3.3 Merck & Co Kidney Cancer or Renal Cancer Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Merck & Co Kidney Cancer or Renal Cancer Product Portfolio
  18. 7.3.5 Merck & Co Recent Developments
  19. 7.4 Roche
  20. 7.4.1 Roche Company Information
  21. 7.4.2 Roche Business Overview
  22. 7.4.3 Roche Kidney Cancer or Renal Cancer Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Roche Kidney Cancer or Renal Cancer Product Portfolio
  24. 7.4.5 Roche Recent Developments
  25. 7.5 Pfizer
  26. 7.5.1 Pfizer Company Information
  27. 7.5.2 Pfizer Business Overview
  28. 7.5.3 Pfizer Kidney Cancer or Renal Cancer Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Pfizer Kidney Cancer or Renal Cancer Product Portfolio
  30. 7.5.5 Pfizer Recent Developments
  31. 7.6 Seagen
  32. 7.6.1 Seagen Company Information
  33. 7.6.2 Seagen Business Overview
  34. 7.6.3 Seagen Kidney Cancer or Renal Cancer Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Seagen Kidney Cancer or Renal Cancer Product Portfolio
  36. 7.6.5 Seagen Recent Developments
  37. 7.7 Merck KGaA
  38. 7.7.1 Merck KGaA Company Information
  39. 7.7.2 Merck KGaA Business Overview
  40. 7.7.3 Merck KGaA Kidney Cancer or Renal Cancer Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Merck KGaA Kidney Cancer or Renal Cancer Product Portfolio
  42. 7.7.5 Merck KGaA Recent Developments
  43. 7.8 GSK
  44. 7.8.1 GSK Company Information
  45. 7.8.2 GSK Business Overview
  46. 7.8.3 GSK Kidney Cancer or Renal Cancer Revenue and Gross Margin (2021-2026)
  47. 7.8.4 GSK Kidney Cancer or Renal Cancer Product Portfolio
  48. 7.8.5 GSK Recent Developments
  49. 7.9 Gilead Sciences
  50. 7.9.1 Gilead Sciences Company Information
  51. 7.9.2 Gilead Sciences Business Overview
  52. 7.9.3 Gilead Sciences Kidney Cancer or Renal Cancer Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Gilead Sciences Kidney Cancer or Renal Cancer Product Portfolio
  54. 7.9.5 Gilead Sciences Recent Developments
  55. 7.10 Eli Lilly
  56. 7.10.1 Eli Lilly Company Information
  57. 7.10.2 Eli Lilly Business Overview
  58. 7.10.3 Eli Lilly Kidney Cancer or Renal Cancer Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Eli Lilly Kidney Cancer or Renal Cancer Product Portfolio
  60. 7.10.5 Eli Lilly Recent Developments
  61. 7.11 Bristol-Myers Squibb
  62. 7.11.1 Bristol-Myers Squibb Company Information
  63. 7.11.2 Bristol-Myers Squibb Business Overview
  64. 7.11.3 Bristol-Myers Squibb Kidney Cancer or Renal Cancer Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Bristol-Myers Squibb Kidney Cancer or Renal Cancer Product Portfolio
  66. 7.11.5 Bristol-Myers Squibb Recent Developments
  67. 7.12 AstraZeneca
  68. 7.12.1 AstraZeneca Company Information
  69. 7.12.2 AstraZeneca Business Overview
  70. 7.12.3 AstraZeneca Kidney Cancer or Renal Cancer Revenue and Gross Margin (2021-2026)
  71. 7.12.4 AstraZeneca Kidney Cancer or Renal Cancer Product Portfolio
  72. 7.12.5 AstraZeneca Recent Developments
  73. 7.13 Amgen
  74. 7.13.1 Amgen Company Information
  75. 7.13.2 Amgen Business Overview
  76. 7.13.3 Amgen Kidney Cancer or Renal Cancer Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Amgen Kidney Cancer or Renal Cancer Product Portfolio
  78. 7.13.5 Amgen Recent Developments
8 North America
  1. 8.1 North America Kidney Cancer or Renal Cancer Revenue (2021-2032)
  2. 8.2 North America Kidney Cancer or Renal Cancer Revenue by Type (2021-2032)
  3. 8.2.1 North America Kidney Cancer or Renal Cancer Revenue by Type (2021-2026)
  4. 8.2.2 North America Kidney Cancer or Renal Cancer Revenue by Type (2027-2032)
  5. 8.3 North America Kidney Cancer or Renal Cancer Revenue Share by Type (2021-2032)
  6. 8.4 North America Kidney Cancer or Renal Cancer Revenue by Application (2021-2032)
  7. 8.4.1 North America Kidney Cancer or Renal Cancer Revenue by Application (2021-2026)
  8. 8.4.2 North America Kidney Cancer or Renal Cancer Revenue by Application (2027-2032)
  9. 8.5 North America Kidney Cancer or Renal Cancer Revenue Share by Application (2021-2032)
  10. 8.6 North America Kidney Cancer or Renal Cancer Revenue by Country
  11. 8.6.1 North America Kidney Cancer or Renal Cancer Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Kidney Cancer or Renal Cancer Revenue by Country (2021-2026)
  13. 8.6.3 North America Kidney Cancer or Renal Cancer Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Kidney Cancer or Renal Cancer Revenue (2021-2032)
  2. 9.2 Europe Kidney Cancer or Renal Cancer Revenue by Type (2021-2032)
  3. 9.2.1 Europe Kidney Cancer or Renal Cancer Revenue by Type (2021-2026)
  4. 9.2.2 Europe Kidney Cancer or Renal Cancer Revenue by Type (2027-2032)
  5. 9.3 Europe Kidney Cancer or Renal Cancer Revenue Share by Type (2021-2032)
  6. 9.4 Europe Kidney Cancer or Renal Cancer Revenue by Application (2021-2032)
  7. 9.4.1 Europe Kidney Cancer or Renal Cancer Revenue by Application (2021-2026)
  8. 9.4.2 Europe Kidney Cancer or Renal Cancer Revenue by Application (2027-2032)
  9. 9.5 Europe Kidney Cancer or Renal Cancer Revenue Share by Application (2021-2032)
  10. 9.6 Europe Kidney Cancer or Renal Cancer Revenue by Country
  11. 9.6.1 Europe Kidney Cancer or Renal Cancer Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Kidney Cancer or Renal Cancer Revenue by Country (2021-2026)
  13. 9.6.3 Europe Kidney Cancer or Renal Cancer Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Kidney Cancer or Renal Cancer Revenue (2021-2032)
  2. 10.2 China Kidney Cancer or Renal Cancer Revenue by Type (2021-2032)
  3. 10.2.1 China Kidney Cancer or Renal Cancer Revenue by Type (2021-2026)
  4. 10.2.2 China Kidney Cancer or Renal Cancer Revenue by Type (2027-2032)
  5. 10.3 China Kidney Cancer or Renal Cancer Revenue Share by Type (2021-2032)
  6. 10.4 China Kidney Cancer or Renal Cancer Revenue by Application (2021-2032)
  7. 10.4.1 China Kidney Cancer or Renal Cancer Revenue by Application (2021-2026)
  8. 10.4.2 China Kidney Cancer or Renal Cancer Revenue by Application (2027-2032)
  9. 10.5 China Kidney Cancer or Renal Cancer Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Kidney Cancer or Renal Cancer Revenue (2021-2032)
  2. 11.2 Asia Kidney Cancer or Renal Cancer Revenue by Type (2021-2032)
  3. 11.2.1 Asia Kidney Cancer or Renal Cancer Revenue by Type (2021-2026)
  4. 11.2.2 Asia Kidney Cancer or Renal Cancer Revenue by Type (2027-2032)
  5. 11.3 Asia Kidney Cancer or Renal Cancer Revenue Share by Type (2021-2032)
  6. 11.4 Asia Kidney Cancer or Renal Cancer Revenue by Application (2021-2032)
  7. 11.4.1 Asia Kidney Cancer or Renal Cancer Revenue by Application (2021-2026)
  8. 11.4.2 Asia Kidney Cancer or Renal Cancer Revenue by Application (2027-2032)
  9. 11.5 Asia Kidney Cancer or Renal Cancer Revenue Share by Application (2021-2032)
  10. 11.6 Asia Kidney Cancer or Renal Cancer Revenue by Country
  11. 11.6.1 Asia Kidney Cancer or Renal Cancer Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Kidney Cancer or Renal Cancer Revenue by Country (2021-2026)
  13. 11.6.3 Asia Kidney Cancer or Renal Cancer Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Kidney Cancer or Renal Cancer Revenue (2021-2032)
  2. 12.2 SAMEA Kidney Cancer or Renal Cancer Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Kidney Cancer or Renal Cancer Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Kidney Cancer or Renal Cancer Revenue by Type (2027-2032)
  5. 12.3 SAMEA Kidney Cancer or Renal Cancer Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Kidney Cancer or Renal Cancer Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Kidney Cancer or Renal Cancer Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Kidney Cancer or Renal Cancer Revenue by Application (2027-2032)
  9. 12.5 SAMEA Kidney Cancer or Renal Cancer Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Kidney Cancer or Renal Cancer Revenue by Country
  11. 12.6.1 SAMEA Kidney Cancer or Renal Cancer Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Kidney Cancer or Renal Cancer Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Kidney Cancer or Renal Cancer Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst